ChristianeQuerfeldMDPhD
Dermatology • Duarte, CADermatopathology
Professor; Dermatology/Dermatopathology; Director, Cutaneous Lymphoma Program
Dr. Querfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-775-3514Fax+1 626-218-5310
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Dermatopathology, 2010 - 2011
University of ChicagoResidency, Dermatology, 2007 - 2010
Good Samaritan Hospital of MarylandInternship, Internal Medicine, 2006 - 2007- McGaw Medical Center of Northwestern UniversityResidency, Dermatology, 2002 - 2004
University of HeidelbergPhD, Microbiology/Immunology, 1995
Univ Cologne- Fac MedClass of 1994
Certifications & Licensure
CA State Medical License 2014 - 2025
NY State Medical License 2011 - 2016
IL State Medical License 2010 - 2014
American Board of Dermatology Dermatology- American Board of Dermatology Dermatopathology
Awards, Honors, & Recognition
- Scholar in Clinical Research Leukemia Lymphoma Society, 2018
- Excellence Award City of Hope, 2017
- Junior Investigator Research Development Award City of Hope, 2016
- Join now to see all
Clinical Trials
- Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome Start of enrollment: 2006 Aug 28
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
- Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Start of enrollment: 2017 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T cell lymphoma.Christiane Querfeld, Joycelynne M Palmer, Zhen Han, Xiwei Wu, Yate-Ching Yuan
Blood Advances. 2025-02-14 - Epstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature.Lori Soma, Liliana Crisan, Jack Reid, Winston Lee, Joo Song
American Journal of Clinical Pathology. 2025-02-12 - Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1.Jonathan S Rink, Adam Y Lin, Andrea E Calvert, David Kwon, Alexandra Moxley
ACS Applied Materials & Interfaces. 2025-01-08
Lectures
- Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression an...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
City of Hope Doctors and Scientists Present Research on Novel Cancer Therapies at American Society of Hematology (ASH) Annual ConferenceDecember 10th, 2024- A Study Associates the Use of Hydroquinone with the Risk of Skin Cancer -News ForestAugust 26th, 2022
- Regional Lymph Nodes Guarded by Immune CellsOctober 4th, 2021
- Join now to see all
Professional Memberships
- Fellow
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
